Core Viewpoint - Baixinan-B (02185) has seen a nearly 10% increase in stock price, currently trading at 7.85 HKD, with a transaction volume of 11.7587 million HKD, following a strategic partnership announcement with Bluestar Medical (002382) for the Iberis RDN system [1] Company Summary - Baixinan has established a "going abroad" cooperation with Bluestar Medical, leveraging its platform capabilities and industry reputation [1] - The Iberis RDN system has achieved commercialization in countries such as Germany, Spain, and Italy, with Germany and France including it in their healthcare insurance [1] - The Iberis RDN system is the only one globally approved for both transradial (TRA) and transfemoral access routes, providing a significant first-mover advantage [1] Industry Summary - Percutaneous renal denervation (RDN) is a new therapeutic device for uncontrolled and resistant hypertension [1] - According to Frost & Sullivan, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032 [1] - The inclusion of the Iberis RDN system in the healthcare insurance of Germany and France is expected to accelerate Baixinan's commercialization efforts [1]
百心安-B再涨近10% 旗下Iberis RDN系统先发优势明显 公司商业化进程有望加速